These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 26032587

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
    Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, Shu F, Gao Y, Yuan L, Zhang Q, Mi M.
    Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.
    Lin X, Zhang Z, Chen JM, Xu YY, Ye HR, Cui J, Fang Y, Jin Y, Zhu DR, Yuan L.
    Genet Mol Res; 2015 Apr 10; 14(2):2940-6. PubMed ID: 25966055
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment with PPARδ agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model.
    Li X, Li J, Lu X, Ma H, Shi H, Li H, Xie D, Dong L, Liang C.
    Int J Mol Med; 2015 Sep 10; 36(3):767-75. PubMed ID: 26133486
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, Chayama K.
    Dig Liver Dis; 2012 Jun 10; 44(6):492-6. PubMed ID: 22265683
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial.
    Hosseinabadi S, Rafraf M, Asghari S, Asghari-Jafarabadi M, Vojouhi S.
    Complement Ther Med; 2020 Mar 10; 49():102290. PubMed ID: 32147076
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot.
    Abdel-Razik A, Mousa N, Shabana W, Refaey M, Elzehery R, Elhelaly R, Zalata K, Abdelsalam M, Eldeeb AA, Awad M, Elgamal A, Attia A, El-Wakeel N, Eldars W.
    Eur J Gastroenterol Hepatol; 2018 Oct 10; 30(10):1237-1246. PubMed ID: 30096092
    [Abstract] [Full Text] [Related]

  • 20. Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial.
    Amanat S, Eftekhari MH, Fararouei M, Bagheri Lankarani K, Massoumi SJ.
    Clin Nutr; 2018 Aug 10; 37(4):1210-1215. PubMed ID: 28647291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.